A detailed history of Strategic Global Advisors, LLC transactions in Genmab A/S stock. As of the latest transaction made, Strategic Global Advisors, LLC holds 8,320 shares of GMAB stock, worth $171,308. This represents 0.04% of its overall portfolio holdings.

Number of Shares
8,320
Holding current value
$171,308
% of portfolio
0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.84 - $28.48 $198,348 - $236,953
8,320 New
8,320 $202,000
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $167,039 - $232,570
4,942 New
4,942 $209,000
Q2 2022

Aug 15, 2022

SELL
$26.83 - $38.57 $3,246 - $4,666
-121 Reduced 1.5%
7,953 $258,000
Q1 2022

May 16, 2022

BUY
$30.95 - $39.68 $3,559 - $4,563
115 Added 1.44%
8,074 $292,000
Q4 2021

Feb 14, 2022

SELL
$35.87 - $47.12 $1.13 Million - $1.49 Million
-31,556 Reduced 79.86%
7,959 $1.42 Million
Q3 2021

Nov 15, 2021

SELL
$41.55 - $48.72 $5,318 - $6,236
-128 Reduced 0.32%
39,515 $1.73 Million
Q2 2021

Aug 12, 2021

BUY
$32.88 - $44.57 $7,398 - $10,028
225 Added 0.57%
39,643 $1.62 Million
Q1 2021

May 14, 2021

BUY
$30.92 - $44.4 $3,277 - $4,706
106 Added 0.27%
39,418 $1.29 Million
Q4 2020

Feb 16, 2021

BUY
$33.66 - $40.76 $112,727 - $136,505
3,349 Added 9.31%
39,312 $1.6 Million
Q3 2020

Nov 13, 2020

SELL
$33.07 - $38.68 $8,498 - $9,940
-257 Reduced 0.71%
35,963 $1.32 Million
Q2 2020

Aug 13, 2020

BUY
$20.05 - $33.89 $81,403 - $137,593
4,060 Added 12.62%
36,220 $1.23 Million
Q1 2020

May 14, 2020

SELL
$17.15 - $25.22 $157,814 - $232,074
-9,202 Reduced 22.25%
32,160 $681,000
Q4 2019

Feb 13, 2020

BUY
$18.88 - $24.14 $780,914 - $998,478
41,362 New
41,362 $924,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Strategic Global Advisors, LLC Portfolio

Follow Strategic Global Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Global Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Global Advisors, LLC with notifications on news.